Comparative Effect Of Curcumin Versus Liposomal Curcumin On Systemic Pro-Inflammatory Cytokines Profile, MCP-1 And RANTES In Experimental Diabetes Mellitus.

PURPOSE: Anti-inflammatory proprieties of curcumin were proved to be useful in various diseases, including diabetes mellitus. The aim of this study was to assess the anti-inflammatory comparative effect of curcumin solution with liposomal curcumin formula, regarding the improvement of serum levels of TNF-α (tumor necrosis factor-alpha), IL-6 (interleukin), IL-1α, IL-1β, MCP-1 (monocyte chemoattractant protein-1) and RANTES in experimental diabetes, induced by streptozotocin (STZ), in rats.
MATERIALS AND METHODS: Six groups of 7 rats were investigated regarding the effect of i.p. (intraperitoneal) administration of two concentrations of curcumin solution (CC1 and CC2) and two concentrations of liposomal curcumin (LCC1 and LCC2): group 1 - control group with i.p. administration of 1 mL saline solution, group 2 - i.p. STZ administration (60mg/kg bw, bw=body weight), group 3 - STZ+CC1 administration, group 4 - STZ+CC2 administration, group 5 - STZ+ LCC1 administration and group 6 - STZ+ LCC2 administration. The concentrations of curcumin formulas were 1 mg/0.1 kg bw for CC1 and LCC1 and 2 mg/0.1 kg bw for CC2 and LCC2, respectively. Serum levels of C-peptide (as an indicator of pancreatic function) and TNF-α, IL-6, IL-1α, IL-1β, MCP-1, and RANTES (as biomarkers for systemic inflammation) were assessed for each group.
RESULTS: The plasma level of C-peptide showed significant improvements when LCC was administrated, with better results for LCC2 when compared to LCC1 (P<0.003). LCC2 pretreatment proved to be more efficient in reducing the level of TNF-α (P<0.003) and RANTES (P<0.003) than CC2 pretreatment. Upon comparing LCC2 with LCC1 formulas, the differences were significant for TNF-α (P=0.004), IL-1β (P=0.022), and RANTES (P=0.003) levels.
CONCLUSION: Liposomal curcumin in a dose of 2 mg/0.1 kg bw proved to have an optimum therapeutic effect as a pretreatment in DM induced by STZ. This result can constitute a base for clinical studies for curcumin efficiency as adjuvant therapy in type 1 DM.

Introduction

Curcumin, a yellow pigment in the Indian spice Turmeric (Curcuma longa), is known for its therapeutic effects and proved its anti‐inflammatory activity through the suppression of oxidative stress, playing a role of scavenger molecule.1 Anti-inflammatory properties of curcumin are only partially related to the anti-oxidative mechanism, having been demonstrated to influence other cell signaling pathways, including the nuclear factor κB (NF‐κB), prostaglandins and pro-inflammatory cytokine production such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-1β.1–4 Based on these facts, numerous researches aim to explore the anti-inflammatory activity of curcumin for a better understanding of their action mechanisms. The main issue of clinical efficacy of curcumin, as adjuvant therapy, is its low bioavailability.4 Therefore, efforts have been dedicated to develop a new curcumin formulation and to study a new administration route for a better bioavailability and tissues distribution.4 Despite its low bioavailability, curcumin proved to be safe and has good tolerability and effectiveness in various human diseases.5 New approaches include the combination of curcumin with adjuvant molecules or designed synthetic analogs.6,7 To overcome its low bioavailability, researchers have also tried to explore new curcumin delivery systems by encapsulating the compound in various micelles, phospholipid complexes, liposomes or nanoparticles structures and to explore parenteral administration routes.6,8–10

Moreover, it has been previously proved that nanocurcumin is efficient in reducing inflammation in streptozotocin (STZ) induced experimental diabetes mellitus (DM).11 Ganugula et al reported that oral administration of curcumin by gavage (both a single dose and multiple doses for 28 days prior DM induction), succeeded in reducing plasma levels of IL‐1α (interleukin), G‐CSF, IL‐10, IL‐17A, IL‐1 β, IL‐6, TNF‐α, IL‐4, GM‐CSF, IFN‐γ, IL‐2, IL‐5, IL‐13, IL‐12p70.11 Water insoluble curcumin is able to forms highly aqueous soluble complexes, with a safe pH.12 In mice, these complexes increased peak plasma concentration of curcumin by 6 times and oral bioavailability by ~20 times.12 Since several animal studies reported that the majority of oral administration of curcumin is excreted in the feces (≤90%),13 a new administration route and formula could improve its bioavailability. Liposomal curcumin nanoformulation has a better bioavailability in various diseases; therefore, it could represent an optimal delivery system for therapies.14 Liposomes consist of phospholipid bilayer vesicles (with a diameter varying from 25 nm to 1000 nm) that can carry both hydrophobic and hydrophilic drugs.15 Intravenous administration of liposomal curcumin was shown to be more efficient due to the enhancement of their stability and targeting proprieties.14 Intraperitoneal administration of curcumin results in a detectable concentration of the compound (by high-performance liquid chromatography) in the brain tissue.16 Based on this report, there is evidence that liposomal curcumin can penetrate even the tight junction of the blood–brain barrier. This characteristic is essential for the potential effect of curcumin on vascular complications of diabetes mellitus. Liposomal formula improved the accumulation of encapsulated drugs in organs and tissues and was demonstrated to increase their therapeutic actions and reduce their side effects.17 Therefore, the pharmaceutical form and the administration route are essential factors for therapeutic efficiency.

To the best of our knowledge, the efficacy of liposomal curcumin formulation was previously assessed only in experimental type 2 diabetes mellitus in rats.18 Diabetes mellitus type 1 is one of the most critical diseases associated with inflammation, which plays an essential role in the β-cell destruction process.19 The clinical symptomatology of type 1 DM is seen when 70–80% of pancreatic beta cells are already destroyed.20 No known biomarkers can assess the pancreatic cells destruction for individuals who are at risk for DM type 1, or for those patients who already developed DM type 1.20 Consequently, one of the most important goals of the current investigations is to find valuable biomarkers in order to evaluate the pancreatic function and inflammation associated with pancreatic insult. After the damage of islet cells, the pancreatic tissue is infiltrated by inflammatory cells that are activated, and as a consequence, pro-inflammatory cytokines are produced.21 An inflammatory reaction will result, triggered and amplified by several molecules that are pro-inflammatory mediators, which are released by different types of cells such as leukocytes, endothelial cells, or injured cells.22 The pro-inflammatory molecules have a critical role in diabetes mellitus complications.23–25 Pro-inflammatory cytokines synthesis can be induced by the excessive production of reactive oxygen species (ROS), via redox-dependent signaling pathways.19 The balance disruption between oxidative stress and anti-oxidative molecules can propagate the destruction of the cells and, consequently, can enhance the inflammatory reaction.

Tumor necrosis factor-alpha (TNF-α) is one of the most important cytokines, produced primarily by activated macrophages, neutrophils, and lymphocytes involved in diabetes mellitus pathogenesis.26 Patients with type 1 DM have been demonstrated to have an increased serum level of TNF-α which contributes to systemic inflammation.27,28 Other various types of pro-inflammatory cytokines such as IL-1β (interleukin), the IL-6 family,29 IL-8, or MCP-1 (monocyte chemoattractant protein-1)30 have been suggested to be involved in DM pathogenesis. Padgett et al19 showed that pro-inflammatory cytokines could be involved in islet cells death by triggering the apoptotic or necrotic process. IL-6 has also been suggested to be a molecule able to regulate the glucose metabolism by acting directly on pancreatic cells and other types of cells such as skeletal muscle cells, adipocytes, hepatocytes, and neuroendocrine cells.29 Besides its functions as a chemoattractant protein, MCP-1 which is produced by inflammatory cells, can also induce cellular death via oxidative stress pathway.31 In addition, Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), a group of molecules contributing to the enrollment of leukocytes in inflammatory process, can also contribute to DM type 1 pathogenesis.32 However, their exact role in the beta-cell destruction mechanism is still under research.32 Beta cells have a temporally limited capacity to recover from cytokine action, by repairing the DNA damage, and by improving insulin secretion if the cytokine action is shorter than 24 hrs.33 After this, irreversible cell destruction will result.33 The pro-inflammatory cytokines stimulate an early necrotic process of islet cells, that can be turned to late apoptosis if the cytokine action is longer than 36 hrs.34 Streptozotocin (STZ) induced DM is one of the most used experimental models to study diabetes mellitus-associated inflammation induced by STZ cytotoxic effect on beta-pancreatic cells.35 Therefore, rapid modulation of pro-inflammatory cytokines could be one of the most important contributors to reducing beta-cells destruction, due to an associated inflammatory process. We previously demonstrated the anti-oxidant properties of curcumin for experimental diabetes mellitus induced by STZ, in oral administration and for liposomal curcumin in i.p. administration.10,36

To go beyond of the previously presented state-of-the-art, the purpose of this study was to assess the effect of intraperitoneal administration of liposomal curcumin in experimental diabetes on C-peptide level (as a marker of pancreatic function) and on pro-inflammatory cytokines (TNF-α, IL-6, IL-1α, IL-1β), MCP-1, and RANTES as markers of systemic inflammatory reaction.

Materials And Methods

All the experimental procedures applied in this study were approved by Ethical Committee of Iuliu Hațieganu University of Medicine and Pharmacy (UMF) Cluj-Napoca, Romania (protocol approval no.0374/16.10.2018) and followed the rules of the European Convention for the protection of Vertebrate Animals used for Experimental and other Scientific Purposes. The animals were procured from the Animal Department of UMF Cluj-Napoca, Romania, and were kept in polypropylene cages at Pathophysiology Department. Wistar-Bratislava albino male rats, weighing 200–250 g with unrestricted access to food (standard pellets from Cantacuzino Institute, Bucharest, Romania) and water were used for this experiment. The animals were kept at constant temperature (24±2°C), humidity (60± 5%) and light-dark regime. All the efforts were made in order to reduce the animals’ suffering and the number used for this experiment.

Preparation Of Liposomal Curcumin

Liposomal-curcumin was encapsulated in long-circulating liposomes (LCL) using the film hydration method with a lipid molar ratio of 9.5:0.5:1 (DPPC:PEG-2000-DSPE:CHO) as previously described.37,38 Briefly, we used 70 mM concentration of phospholipids of which 66.5 mM 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), the main lipid, and 3.5 mM N-(carbonyl-methoxypolyethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (PEG-2000-DSPE), to obtain long circulation properties for a higher efficiency. Further, cholesterol was added to the mixture, resulting in 10:1 phospholipids to cholesterol molar ratio. Resulting PEG-coated nanoliposomes had a size around 140 nm; polydispersity value, close to 0.1; and a zeta potential of about −50 mV. The particle size and particle size distribution of liposomes were determined by dynamic light scattering using a Zetasizer Nano ZS instrument (Malvern Instruments, Malvern, UK). Immediately after the preparation, the size, size distribution, and surface charge of the liposomes were determined, upon dilution in a ratio of 1:100. The method assigns an efficient encapsulation of curcumin into the liposomes. The resulting liposomal curcumin nanoparticles contained a relatively high concentration of curcumin, around 4.7 mg/mL, with an high efficiency, close to 80%.

The proposed formulation had appropriate quality attributes for intraperitoneal administration, such as monodisperse size around 140 nm and zeta potential about −50 mV. The same concentration of curcumin solution was freshly prepared by dissolution in 96% (v/v) ethanol and further dilution with saline, in order to observe if liposomal encapsulation curcumin had an increased therapeutic effect compared to curcumin solution. Curcumin (CC) and cholesterol were purchased from Sigma-Aldrich Co (St. Louis, MO, USA). 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, ≥99% [TP-PC]) and N-(carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3phosphoethanolamine (PEG-2000-DSPE, ≥98% [HPLC]) sodium salt were purchased from Lipoid GmbH (Ludwigshafen, Germany).

Experimental Protocol

Six groups of male rats, as presented in Figure 1 were evaluated.

Figure 1

Group flow chart: experimental design.

Abbreviations: i.p., intraperitoneal administration; bw, body weight.

Streptozotocin was administrated as a single dose by intraperitoneal route (60 mg/kg bw – 1 mL solution) after dissolving it in freshly prepared 0.01 M citrate buffer (pH=4.5) solution.39 All curcumin treatments were made 30 mins before STZ administration.10 A single dose of curcumin was administrated in our study since previous studies demonstrated the efficacity of one prophylactic dose of curcumin in various form (curcumin-capped iron oxide nanoparticles40 or liposomal curcumin10) and in different pathological conditions such as: nano-curcumin in type 1 DM,11 injected microparticles of curcumin in cancer,41 or type 1 DM.42 All the animals with plasma glucose above 200 mg/dL at 72 hrs were considered diabetic and were included in the study.11 Streptozotocin was purchased from Sigma-Aldrich Co. (St Louis, MO, USA).

Blood Collection And Pancreatic Function Assessment

The blood parameters were assessed from samples collected from the retro-orbital plexus of each animal, under ketamine anaesthesia (5 mg/kg bw, i.p. route)43 at the end of the experiment (72 hrs). The effect of liposomal curcumin on glycemia (as a parameter of pancreatic function), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (as parameters of liver cell damage) have already been reported.10 The serum C-peptide was measured as marker of pancreatic beta-cell function. C-peptide (connecting peptide) connects insulin’s A-chain to its B-chain in proinsulin molecule. It is co-secreted with insulin by pancreatic β-cells following glucose stimulation, and it is a good indicator of pancreatic function.44,45 The C-peptide determination was done with the ELISA method (kit purchased from Elabscience, USA).

Multiplex Assay For Cytokines

The serum assessment for tumour necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), interleukin-1 alpha (IL-1 α), interleukin-1 beta (IL-1 β), monocyte chemoattractant protein-1 (MCP-1), and regulated upon activation, normal T cell expressed and secreted (RANTES), was made by ELISA technique (Stat Fax 303 Plus Microstrip Reader, Minneapolis, USA) with a kit purchased from Signosis Inc., Santa Clara, CA, USA.

Statistical Analysis

Statistical analysis was applied to the raw data of the investigated biomarkers. Descriptive statistics, represented by mean and standard deviation, was reported for the investigated biomarkers. The number of rats per group imposed the application of non-parametric methods when the STZ groups were compared (as the Kruskal–Wallis test) or when two groups were compared (the Mann–Whitney test). The number of investigated groups was used to adjust the significance level, and a p-value of less than 0.01 was considered statistically significant. The variability of biomarkers by groups was graphically represented with box-and-whiskers with the line in the box given by the value of median, x representing the value of the mean, the lower and upper box as 1st and 3rd quartile, and the whiskers as the minimum and maximum values. Statistica program (v. 13.5, StatSoft, Tulsa, OK, USA) was used to perform the analysis.

Results

All the rats included in the study were analyzed. The values of C-peptide show the damage induced by STZ, with significant differences between diabetic rats (Kruskal–Wallis ANOVA: statistics = 22.88; P = 0.0001) and significant smaller values (see Figure 2A) for each group as compared to the control group (two-group comparisons by Mann–Whitney test: P-values = 0.0022). The values of TNF-α (Figure 2B), IL-6 (Figure 2C), IL-1α (Figure 2D), IL-1ß (Figure 2E), MCP-1 (Figure 2F), and RANTES (Figure 2G) were significantly higher in the STZ group compared to the control group (P-value < 0.0001).

Figure 2

Variability of the biomarkers by groups: (A) C-Peptide; (B) tumor necrosis factor-alpha (TNF-α); (C) interLeukin 6 (IL-6); (D) interLeukin 1 alpha (IL-1α); (E) interLeukin 1 beta (IL-1β); (F) monocyte chemoattractant protein-1 (MCP-1); (G) regulated on activation, normal t cell expressed and secreted (RANTES); Control; STZ = streptozotocin-induced type 1 diabetes; STZ+CCx = streptozotocin-induced type 1 diabetes with curcumin solution pre-treatment at 1 mg/0.1 kg bw (x=1, CC1), respectively, 2 mg/0.1 kg bw (x=2, CC2); STZ+LCCx = streptozotocin-induced type 1 diabetes with liposomal curcumin pre-treatment at 1 mg/0.1 kg bw (x=1, LCC1) respectively, 2 mg/0.1 kg bw (x=2, LCC2).

Abbreviations: TNF-α, tumour necrosis factor-alpha; IL-6, interleukin 6; IL-1α, interleukin-1 alpha; IL-1β, interleukin-1 beta; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated upon activation, normal T cell expressed and secreted.

Kruskal–Wallis test identified significant differences among STZ, STZ+CC1, STZ+CC2, STZ+LCC1, and STZ+LCC2 groups for all investigated markers: C-Peptide (Stat = 22.88; P-value = 0.0001), TNF-α (Stat = 25.15; P-value < 0.0001), IL-6 (Stat = 13.76; P-value = 0.0081), IL-1α (Stat = 19.75; P-value = 0.0006), IL-1β (Stat = 27.81; P-value < 0.0001), MCP-1 (Stat = 16.90; P-value = 0.0020), RANTES (Stat = 28.22; P-value < 0.0001).

Discussions

Curcumin And Pancreatic Function Alleviation

The question of this study was whether different levels of C-peptide, pro-inflammatory cytokines (TNF-α, IL-6, IL-1α, IL-1ß), MCP-1, and RANTES could be useful to assess the efficiency of curcumin pretreatment in two pharmaceutical formulas, and two different concentrations, in STZ-induced type 1 DM in rats. To the extent of our knowledge, this is the first study of assessing the anti-inflammatory efficacy of liposomal curcumin administration by intraperitoneal route in STZ-induced type 1 DM in rats.

We found that the C-peptide level in the group with STZ and CC and LCC administration was improved compared to STZ group with better results for LCC when compared to CC solution (Table 1, Figure 2). We also obtained better results for C-peptide level with LCC2 pretreatment when compared to LCC1 (P-value =0.0022) (Table 1, Figure 2A) proving that curcumin acts in a dose-dependent manner. The significant improvement of C-peptide in groups pretreated with curcumin show that the pancreatic beta-cell function can be partially preserved by this therapy with better results for a higher concentration of liposomal curcumin. The value of C-peptide can offer a measure of pancreatic cell activity that is preferable to insulin measurement because of the slower metabolic clearance rate (half-life of 20–30 mins, compared to the half-life of insulin of just 3–5 mins); it is also preferred in humans, because of the lack of cross-reactivity with antibodies to insulin.46 Due to a lower metabolic rate of C-peptide, compared to the metabolic rate of insulin, C-peptide provides a more stable test window of fluctuating beta-cell response.47 C-peptide results from pro-insulin in equimolar concentration with insulin.45,48 After the cleavage of proinsulin, insulin and C-peptide are produced in pancreatic beta cells in equal amounts.47 Therefore, the evaluation of the C-peptide as an indicator of pancreatic function demonstrated that curcumin administration prior to STZ can improve the pancreatic production of insulin. Rat islet amyloid polypeptide (hIAPP) aggregation (rIAPP) is a new approach that also could serve as biomarker in experimental studies for therapeutic agent efficacy assessment.49 This new molecular perspective regarding the early processes associated with islet cells destruction could bring a better understanding of pathophysiological mechanisms involved in type 1 DM.

Table 1

Variability In The Investigated Marker Of Pancreatic Damage, And Cytokines By Groups Expressed As Mean And Standard Deviation

	Group Abbreviation (7 rats per group)
C	STZ	STZ+CC1	STZ+CC2	STZ+LCC1	STZ+LCC2
Marker of pancreatic damage
C-Peptide (pmol/L) Mean (STD) P-value* P-value** P-value***	609 (14.80)	426 (12.91)	436 (9.69)0.1417	443 (11.19)0.0298	448 (12.14)0.01270.1059	557 (11.00)0.00220.00220.0022
Markers of inflammation
TNF-α (ng/mL) Mean (STD) P-value* P-value** P-value***	0.45 (0.07)	4.03 (0.35)	3.73 (0.26)0.1102	3.49 (0.35)0.0253	3.13 (0.39)0.00400.0106	2.17 (0.35)0.00220.00220.0040
IL-6 (ng/mL) Mean (STD) P-value* P-value** P-value***	0.29 (0.03)	0.44 (0.04)	0.41 (0.02)0.1599	0.40 (0.01)0.0553	0.38 (0.03)0.01520.0967	0.36 (0.04)0.01060.09670.4062
IL-1α (ng/mL) Mean (STD) P-value* P-value** P-value***	0.39 (0.04)	0.60 (0.07)	0.50 (0.05)0.0181	0.49 (0.04)0.0060	0.47 (0.06)0.00600.2248	0.41 (0.05)0.00220.01810.0845
IL-1ß (ng/mL) Mean (STD) P-value* P-value** P-value***	0.47 (0.12)	1.77 (0.12)	1.61 (0.04)0.0033	1.48 (0.05)0.0022	1.35 (0.21)0.00600.0298	1.04 (0.21)0.00220.00270.0215
MCP-1 (ng/mL) Mean (STD) P-value* P-value** P-value***	0.26 (0.05)	0.44 (0.05)	0.40 (0.02)0.1102	0.37 (0.03)0.0106	0.39 (0.05)0.06390.7983	0.33 (0.03)0.00270.07360.0409
RANTES (ng/mL) Mean (STD) P-value* P-value** P-value***	1.73 (0.07)	3.35 (0.24)	3.13 (0.16)0.0639	2.97 (0.21)0.0152	2.60 (0.17)0.00220.0022	2.11 (0.13)0.00220.00220.0027

Notes: P-values from Mann–Whitney test: *As compared to STZ-C; **For comparison of STZ+CC1 with STZ+LCC1, respectively, STZ+CC2 with STZ+LCC2; ***For comparison between groups with different doses of LLC (STZ+LCC1 with STZ+LCC2).

Abbreviations: STD, standard deviation; C, Control; STZ, streptozotocin-induced type 1 diabetes; STZ+CC1, STZ and 1 mg/0.1 kg bw curcumin as pre-treatment; STZ+CC2, STZ and 2 mg/100g bw curcumin as pre-treatment; STZ+LCC1, STZ and pre-treatment with 1 mg/100g bw liposomal-curcumin; STZ+LCC2, STZ and pre-treatment with 2 mg/0.1 kg bw liposomal-curcumin; Std, standard deviation; TNF-α, tumour necrosis factor-alpha; IL-6, interleukin 6; IL-1α, interleukin-1 alpha; IL-1β, interleukin-1 beta; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated upon activation, normal T cell expressed and secreted.

Moreover, data from experimental studies in rats showed that C-peptide is beneficial for the effect of insulin on glycemia and glucose utilization.50–52 These effects could be explained by the increased utilization of glucose due to increased muscle glucose uptake, but the exact pathway involved in this effect of C-peptide is still unknown.53 Experimental studies demonstrated that the effect of C-peptide on lipidic metabolism consists in reducing lipolysis in diabetic rats.54 Still, the effect of C-peptide on lipolysis in non-diabetic conditions has been showed to be insignificant.55 On a different note, the effect of C-peptide on circulation consists in a vasodilator effect (due to the enhancement of nitric oxide synthesis by increasing the expression of endothelial nitric oxide synthase).56 Thus, C-peptide exerts a protective role against DM microvascular complications such as diabetic retinopathy,57 diabetic nephropathy,58 or diabetic neuropathy.57 Low or undetectable levels of C-peptide are associated with severe forms of diabetic retinopathy, namely proliferative retinopathy.59,60 The nephroprotective effect of C-peptide is related to the decrease of apoptosis induced by pro-inflammatory cytokines61 and to the interaction with the signaling pathway of growth factors.62 C-peptide can improve sensory, and motor nerve conduction velocity in STZ-induced diabetes in rats63 and can reduce the neural Na+,K+-ATPase defect in the hippocampus.64 The preservation of C-peptide secretion can result in better metabolic control and less microvascular complications.65 The C-peptide can also have a protective effect on vasculature against inflammation in type 1 DM.66 Therefore, the partial preservation of C-peptide production by beta-pancreatic cells by curcumin administration, proved by our study, can constitute a valuable strategy in DM treatment. Moreover, C-peptide assessment could bring valuable information regarding the risk of microvascular complications in DM.

Liposomal Curcumin Effect On Proinflammatory Cytokines

The data presented in this study showed a statistically significant (Table 1) increase in proinflammatory cytokines (TNF-α – Figure 2B, IL-6 – Figure 2C, IL-1α – Figure 2D, and IL-1β – Figure 2E) after STZ administration. Some reports suggested that the increase of oxidative stress molecules due to STZ administration can induce and can constitute biochemical markers for the pathogenesis of type 1 DM.10,67 Fatima et al58 also found decreased levels of catalase and superoxide dismutase in patients with type 1 DM, suggesting a reduced antioxidant activity. Particularly, nitro-oxidative stress enhancement, by increasing the production of NO, contributes to the injury of pancreatic beta cells, and to the cell death by apoptosis and necrosis.68 On the other hand, hyperglycemia itself can be considered responsible for molecular and cellular damages.69 Due to the impossibility to regulate their intracellular level of glucose (consequently to the lack of insulin) cells are vulnerable to hyperglycemia, which can lead to changes in their redox status.69 Cells’ redox status disequilibrium is closely related to the enhancement of pro-inflammatory activity because the energy metabolism of the cells and the redox state are intrinsically related.70 In fact, decreased intracellular glucose increases ROS production and substantially contributes to inflammatory reaction initiation and cell apoptosis.70 Activated macrophages and neutrophils arrived at the inflammation site, are the primary sources of ROS generation and pro-inflammatory cytokines production.71 Two types of macrophages have been described, the classically activated macrophages that produce pro-inflammatory cytokines (inducing insulitis and beta-cells death by apoptosis and necrosis) and alternatively activated macrophages, with anti-inflammatory activity, both showing an important role in type 1 and type 2 DM pathogenesis.71 The imbalance between these two types of macrophages could represent an important mechanism involved in diabetes mellitus pathogenesis. Activation of different signaling pathways in inflammatory cells is associated with increased production of IL-1β, IL-6, and TNF-α.72 Our results also demonstrated a significant increase of TNF-α, IL-6, IL-1α, and IL-1β after STZ administration. We also found that the effectiveness of curcumin pretreatment depends on the formula (LCC2 was more effective than CC2 for TNF-α, IL-1β levels improvement; P<0.01) (Figure 2, Table 1). Dose-related effectiveness was demonstrated by the significant decrease of TNF-α level by LCC2 when compared to LCC1 pretreatment (P<0.01) (Table 1, Figure 2B). Ganugula et al11 demonstrated that oral administration of nanocurcumin was proved to be efficient in the pancreatic function improvement after STZ-induced diabetes in mice, in a dose-dependent manner. Multiple assays of several pro-inflammatory cytokines (IL‐1 α, G‐CSF, IL‐10, IL‐17A, IL‐1β, IL‐6, TNF‐α, IL‐4, GM‐CSF, IFN γ, IL‐2, IL‐5, IL‐13, IL‐12p70) demonstrated that both curcumin and nanocurcumin successfully reduce their production in pancreatic tissue in STZ-induced diabetes in mice.11 In vitro study reported that tetrahydrocurcumin (THC), one of the primary metabolites of curcumin, has antioxidant and anti-inflammatory activities reducing islet cell apoptosis and improving their viability after being exposed to TNF-α, interferon-β, and IL-1.73 A clinical study has already demonstrated that oral administration of curcumin combined with piperine could reduce the serum level of TNF-α in diabetic patients, after 12 weeks of treatment.74 A curcumin derivate, J147, showed the efficacy in ameliorating neuropathy in the streptozotocin-induced mouse model of type 1 DM.75 Oral curcumin administration proved to reduce diabetic allodynia and hyperalgesia by decreasing the expression of both TNF-α and TNF-α receptor 1 in diabetic rats.76 Another therapeutic formula, poly(D,L-lactic-co-glycolic acid)–based curcumin nanoparticles with encapsulated coenzyme Q10, proved to reduce TNF-α due to the increase of its oral bioavailability and therapeutic efficacy.77

Induced apoptosis of pancreatic beta cells by ROS is associated with the secretion of monocyte chemoattractant protein-1 (MCP-1/CCL2), a member of the C-C chemokine family, and a potent chemotactic factor for monocytes.78,79 MCP-1 will recruit more macrophages, dendritic cells, and T cells into the pancreatic tissue.78 In our study, the significant increase of MCP-1 due to STZ administration was substantially reduced by LCC pretreatment, LCC2 being more efficient than LCC1 (Table 1, Figure 2F). As an illustration, using an experimental mouse model for diabetes induced by STZ, Cvetkovic et al80 demonstrated that MCP-1 is increased in plasma of diabetic mice and inhibition of this molecule can reduce the insulitis. Admittedly, classically activated macrophages, CD4+, and CD8+ lymphocytes are the first cells that arrive in damaged pancreatic tissue and substantially contribute to pancreatic inflammation and consequently increased pro-inflammatory cytokines and MCP-1 production.72 It is considered that one of the most important triggers for pro-inflammatory cytokine production is the activation of NF-kβ, which promotes the expression of pro-inflammatory cytokines.81 Curcumin has been proved to be able to modulate the NF-kβ pathway.82 A possible mechanism that enhanced the curcumin effect on pro-inflammatory cytokine levels can be represented by the reduced associated oxidative stress,10 which is in turn related to the reduction of NF-kβ pathway signalling.83

Furthermore, RANTES is a pro-inflammatory chemokine that is a selective attractant for memory T lymphocytes and monocytes, and plays an important role in inflammation.84 Our study results demonstrated a significant reduction in RANTES molecules for both pretreated groups with LCC1 and LCC2, with a better result for LCC2 administration (Table 1, Figure 2G). During insulitis, CD8+ and CD4+ cells are considered to be among the mediators that contribute to beta-cells destruction.85,86 The infiltration of the pancreas with T-cells takes place during the inflammatory phase of type 1 DM.87 CD8+ lymphocytes are the most abundant cells in the inflammatory infiltrate during insulitis.87 Subsequently, the progression of beta-cells destruction is proportional to the infiltration of the pancreatic tissue with CD8+ and pro-inflammatory cytokines, which are partially dependent on the intensity of the oxidative stress.88 RANTES may also promote the infiltration of the liver with NK cells during insulitis, being associated with beta-cells destruction.89 Even though infiltrating immune cells are considered to hurt beta-cells, there is evidence that they can also contribute to beta-cells proliferation and can delay the DM type 1 onset, but the mechanism is not yet fully understood.89 The inflammatory infiltrates accumulation could represent a defense mechanism activated against pancreatic insult, and the preservation of the integrity of this mechanism could constitute a starting point for future therapies.89 Identification of the exact functional contribution of immune cells subset, and of cytokine and chemokine overproduction, can contribute to reducing the beta-cells destruction in type 1 DM.

Regarding the mechanism involved, our data results suggest that liposomal curcumin is able to reduce the pro-inflammatory cytokines production (TNF-α, IL-6, IL-1α, IL-1β, MCP-1, and RANTES) in STZ-induced diabetes in rats, having a favorable functional outcome on pancreatic beta cells function. That was demonstrated by improved plasma levels of C-peptide. Our results showed that the anti-inflammatory effect of curcumin therapy depends on curcumin concentration and their pharmaceutical formula. Once the anti-inflammatory effect or liposomal curcumin has been demonstrated further studies could be conducted to measure the products of metabolism at the level of blood and/or tissues and to elucidate the exact mechanism of curcumin. Furthermore, mechanism studies could be conducted to demonstrate the anti-inflammatory effects of different forms of curcumin (standard, liposomal, nano, micro, etc.). A comparative study regarding various formulas of curcumin would be useful to establish the best delivery system with the highest bioavailability and specific activities on DM experimental models. Moreover, Westen Blood experiments using anti-amylin and anti-oligomer antibodies could bring more inside on the efficacy of different curcumin formulations and on relation with pancreatic and liver function as well as systemic pro-inflammatory cytokines profile, MCP-1 and RANTES in experimentally induced diabetes mellitus.

Conclusion

The liposomal curcumin formula was demonstrated to be more efficient than curcumin solution in pancreatic function preservation and is able to reduce the levels of pro-inflammatory cytokines (TNF-α, IL-6, IL-1α, IL-1β), MCP-1 and RANTES associated with STZ-induced type 1 DM in rats. The decrease in cytokines and improvements of C-peptide level proved better for liposomal curcumin formula and acted in a dose-dependent manner. The efficiency of liposomal curcumin administration has to be tested in humans, as adjuvant therapy for type 1 DM patients. Any effort to improve the formula for a better curcumin bioavailability can bring this natural product closer to its use in clinical practice. Natural products therapies added to drugs treatment could constitute a future therapeutic strategy for diabetic patients.